Literature DB >> 23085085

Histone deacetylase 3 is required for maintenance of bone mass during aging.

Meghan E McGee-Lawrence1, Elizabeth W Bradley, Amel Dudakovic, Samuel W Carlson, Zachary C Ryan, Rajiv Kumar, Mahrokh Dadsetan, Michael J Yaszemski, Qingshan Chen, Kai-Nan An, Jennifer J Westendorf.   

Abstract

Histone deacetylase 3 (Hdac3) is a nuclear enzyme that removes acetyl groups from lysine residues in histones and other proteins to epigenetically regulate gene expression. Hdac3 interacts with bone-related transcription factors and co-factors such as Runx2 and Zfp521, and thus is poised to play a key role in the skeletal system. To understand the role of Hdac3 in osteoblasts and osteocytes, Hdac3 conditional knockout (CKO) mice were created with the osteocalcin (OCN) promoter driving Cre expression. Hdac3 CKO(OCN) mice were of normal size and weight, but progressively lost trabecular and cortical bone mass with age. The Hdac3 CKO(OCN) mice exhibited reduced cortical bone mineralization and material properties and suffered frequent fractures. Bone resorption was lower, not higher, in the Hdac3 CKO(OCN) mice, suggesting that primary defects in osteoblasts caused the reduced bone mass. Indeed, reductions in bone formation were observed. Osteoblasts and osteocytes from Hdac3 CKO(OCN) mice showed increased DNA damage and reduced functional activity in vivo and in vitro. Thus, Hdac3 expression in osteoblasts and osteocytes is essential for bone maintenance during aging.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23085085      PMCID: PMC3513670          DOI: 10.1016/j.bone.2012.10.015

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  48 in total

1.  Deacetylation of p53 modulates its effect on cell growth and apoptosis.

Authors:  J Luo; F Su; D Chen; A Shiloh; W Gu
Journal:  Nature       Date:  2000-11-16       Impact factor: 49.962

2.  Histone deacetylases specifically down-regulate p53-dependent gene activation.

Authors:  L J Juan; W J Shia; M H Chen; W M Yang; E Seto; Y S Lin; C W Wu
Journal:  J Biol Chem       Date:  2000-07-07       Impact factor: 5.157

3.  Spatial distribution of Bax and Bcl-2 in osteocytes after bone fatigue: complementary roles in bone remodeling regulation?

Authors:  Olivier Verborgt; Nadine A Tatton; Robert J Majeska; Mitchell B Schaffler
Journal:  J Bone Miner Res       Date:  2002-05       Impact factor: 6.741

4.  Contribution of mineral to bone structural behavior and tissue mechanical properties.

Authors:  Eve Donnelly; Dan X Chen; Adele L Boskey; Shefford P Baker; Marjolein C H van der Meulen
Journal:  Calcif Tissue Int       Date:  2010-08-22       Impact factor: 4.333

5.  The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation.

Authors:  Kazuhisa Nakashima; Xin Zhou; Gary Kunkel; Zhaoping Zhang; Jian Min Deng; Richard R Behringer; Benoit de Crombrugghe
Journal:  Cell       Date:  2002-01-11       Impact factor: 41.582

6.  Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip.

Authors:  R S Weinstein; R W Nicholas; S C Manolagas
Journal:  J Clin Endocrinol Metab       Date:  2000-08       Impact factor: 5.958

7.  Runx3/AML2/Cbfa3 regulates early and late chondrocyte differentiation.

Authors:  Do Y Soung; Yufeng Dong; YongJun Wang; Michael J Zuscik; Edward M Schwarz; Regis J O'Keefe; Hicham Drissi
Journal:  J Bone Miner Res       Date:  2007-08       Impact factor: 6.741

8.  Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization.

Authors:  Mei Zhang; Shouhong Xuan; Mary L Bouxsein; Dietrich von Stechow; Nagako Akeno; Marie Claude Faugere; Hartmut Malluche; Guisheng Zhao; Clifford J Rosen; Argiris Efstratiadis; Thomas L Clemens
Journal:  J Biol Chem       Date:  2002-09-04       Impact factor: 5.157

9.  Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter.

Authors:  Jennifer J Westendorf; S Kaleem Zaidi; Jonathan E Cascino; Rachel Kahler; André J van Wijnen; Jane B Lian; Minoru Yoshida; Gary S Stein; Xiaodong Li
Journal:  Mol Cell Biol       Date:  2002-11       Impact factor: 4.272

10.  Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism.

Authors:  Teresita Bellido; A Afshan Ali; Lilian I Plotkin; Qiang Fu; Igor Gubrij; Paula K Roberson; Robert S Weinstein; Charles A O'Brien; Stavros C Manolagas; Robert L Jilka
Journal:  J Biol Chem       Date:  2003-10-01       Impact factor: 5.157

View more
  44 in total

Review 1.  Histone Deacetylases in Bone Development and Skeletal Disorders.

Authors:  Elizabeth W Bradley; Lomeli R Carpio; Andre J van Wijnen; Meghan E McGee-Lawrence; Jennifer J Westendorf
Journal:  Physiol Rev       Date:  2015-10       Impact factor: 37.312

Review 2.  Chromatin modifiers and histone modifications in bone formation, regeneration, and therapeutic intervention for bone-related disease.

Authors:  Jonathan A R Gordon; Janet L Stein; Jennifer J Westendorf; Andre J van Wijnen
Journal:  Bone       Date:  2015-03-31       Impact factor: 4.398

Review 3.  Conditional deletion of Hdac3 in osteoprogenitor cells attenuates diet-induced systemic metabolic dysfunction.

Authors:  Meghan E McGee-Lawrence; Thomas A White; Nathan K LeBrasseur; Jennifer J Westendorf
Journal:  Mol Cell Endocrinol       Date:  2015-02-07       Impact factor: 4.102

4.  Expression of the ectodomain-releasing protease ADAM17 is directly regulated by the osteosarcoma and bone-related transcription factor RUNX2.

Authors:  Héctor F Araya; Hugo Sepulveda; Carlos O Lizama; Oscar A Vega; Sofia Jerez; Pedro F Briceño; Roman Thaler; Scott M Riester; Marcelo Antonelli; Flavio Salazar-Onfray; Juan Pablo Rodríguez; Ricardo D Moreno; Martin Montecino; Martine Charbonneau; Claire M Dubois; Gary S Stein; Andre J van Wijnen; Mario A Galindo
Journal:  J Cell Biochem       Date:  2018-06-19       Impact factor: 4.429

Review 5.  Functional impairment of bone formation in the pathogenesis of osteoporosis: the bone marrow regenerative competence.

Authors:  Joseph P Bidwell; Marta B Alvarez; Mark Hood; Paul Childress
Journal:  Curr Osteoporos Rep       Date:  2013-06       Impact factor: 5.096

6.  Kynurenine, a Tryptophan Metabolite That Accumulates With Age, Induces Bone Loss.

Authors:  Mona El Refaey; Meghan E McGee-Lawrence; Sadanand Fulzele; Eileen J Kennedy; Wendy B Bollag; Mohammed Elsalanty; Qing Zhong; Ke-Hong Ding; Nathaniel G Bendzunas; Xing-Ming Shi; Jianrui Xu; William D Hill; Maribeth H Johnson; Monte Hunter; Jessica L Pierce; Kanglun Yu; Mark W Hamrick; Carlos M Isales
Journal:  J Bone Miner Res       Date:  2017-08-14       Impact factor: 6.741

7.  Histone deacetylase 3 suppresses Erk phosphorylation and matrix metalloproteinase (Mmp)-13 activity in chondrocytes.

Authors:  Lomeli R Carpio; Elizabeth W Bradley; Jennifer J Westendorf
Journal:  Connect Tissue Res       Date:  2016-09-23       Impact factor: 3.417

8.  Sclerostin deficient mice rapidly heal bone defects by activating β-catenin and increasing intramembranous ossification.

Authors:  Meghan E McGee-Lawrence; Zachary C Ryan; Lomeli R Carpio; Sanjeev Kakar; Jennifer J Westendorf; Rajiv Kumar
Journal:  Biochem Biophys Res Commun       Date:  2013-11-06       Impact factor: 3.575

9.  The glucocorticoid receptor in osteoprogenitors regulates bone mass and marrow fat.

Authors:  Jessica L Pierce; Ke-Hong Ding; Jianrui Xu; Anuj K Sharma; Kanglun Yu; Natalia Del Mazo Arbona; Zuleika Rodriguez-Santos; Paul Bernard; Wendy B Bollag; Maribeth H Johnson; Mark W Hamrick; Dana L Begun; Xing M Shi; Carlos M Isales; Meghan E McGee-Lawrence
Journal:  J Endocrinol       Date:  2019-07-01       Impact factor: 4.286

10.  Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium.

Authors:  Zachary C Ryan; Hemamalini Ketha; Melissa S McNulty; Meghan McGee-Lawrence; Theodore A Craig; Joseph P Grande; Jennifer J Westendorf; Ravinder J Singh; Rajiv Kumar
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-25       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.